Cyltezo Interactions
There are 480 drugs known to interact with Cyltezo (adalimumab), along with 8 disease interactions. Of the total drug interactions, 285 are major, 188 are moderate, and 7 are minor.
- View all 480 medications that may interact with Cyltezo
- View Cyltezo disease interactions (8)
Most frequently checked interactions
View interaction reports for Cyltezo (adalimumab) and the medicines listed below.
- Afinitor (everolimus)
- amlodipine
- ashwaganda
- azathioprine
- Bactrim DS (sulfamethoxazole / trimethoprim)
- Baraclude (entecavir)
- biotin
- buspirone
- Chantix (varenicline)
- Cimzia (certolizumab)
- Contrave (bupropion / naltrexone)
- Dificid (fidaxomicin)
- Entyvio (vedolizumab)
- Epivir (lamivudine)
- Epivir-HBV (lamivudine)
- gabapentin
- Genvoya (cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide)
- Hepsera (adefovir)
- Inflectra (infliximab)
- Latuda (lurasidone)
- leflunomide
- Lipitor (atorvastatin)
- lisinopril
- mesalamine
- metformin
- Myfortic (mycophenolic acid)
- naproxen
- Ocaliva (obeticholic acid)
- octreotide
- Paxil CR (paroxetine)
Cyltezo disease interactions
There are 8 disease interactions with Cyltezo (adalimumab) which include:
- infections
- malignancies
- neurologic reactions
- tuberculosis
- CHF
- COPD
- hematologic abnormalities
- hepatitis B
Report options
QR code containing a link to this page
More about Cyltezo (adalimumab)
- Cyltezo consumer information
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: TNF alfa inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
